Answer
Among 1,153 patients treated with pirtobrutinib (Jaypirca), the two most common adverse reactions of any grade were neutropenia (27.4%) and haemorrhage (20.4%).
Sources for this answer
- Jaypirca 50mg, 100mg film-coated tabletsEli Lilly and Company Limited · emc · SmPC §4.8 Undesirable effects · Version 4Document updated
Sources checked